Long-Term Cardiovascular Outcomes of Multisystem Inflammatory Syndrome in Children Associated with COVID-19 Using an

Abhishek Chakraborty1,2, Jason N Johnson3,4,5, Jonathan Spagnoli6

  • 1Division of Pediatric Cardiology, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, USA. dr.abhishek.chakraborty@gmail.com.

Pediatric Cardiology
|October 10, 2022
PubMed

Insights

Multisystem inflammatory syndrome in children (MIS-C) can cause heart issues. While most cardiovascular problems resolve within six weeks, some children may experience persistent diastolic dysfunction, coronary artery abnormalities, or myocardial scarring, necessitating long-term monitoring.

Area of Science:

  • Pediatric Cardiology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Cardiovascular involvement is a significant cause of morbidity in children with Multisystem Inflammatory Syndrome (MIS-C).
  • Understanding the long-term cardiovascular sequelae of MIS-C is crucial for patient management.

Purpose of the Study:

  • To identify and characterize the long-term cardiovascular manifestations in children following MIS-C.
  • To assess the resolution patterns of cardiac dysfunction and abnormalities post-MIS-C.

Main Methods:

  • Prospective follow-up of 80 pediatric intensive care unit patients with MIS-C for one year.
  • Evaluation included cardiac biomarkers (troponin, BNP), ECG, echocardiography, cardiovascular magnetic resonance (CMR), and graded-exercise stress testing (GXT).

Main Results:

  • Elevated BNP and troponin levels at disease peak normalized by 6 weeks post-discharge.
  • Systolic dysfunction improved significantly by discharge, with complete resolution in most by 2 weeks.
  • Coronary artery abnormalities resolved in most by 2 weeks post-discharge, with one persistent giant aneurysm at 1 year. CMR revealed persistent late gadolinium enhancement in 17.4% of patients at 6 months.

Conclusions:

  • Cardiovascular manifestations of MIS-C are heterogeneous, with most resolving within 6 weeks.
  • A small subset of patients may experience persistent diastolic dysfunction, coronary artery abnormalities, or myocardial scarring.
  • Structured long-term follow-up is warranted for children with MIS-C to monitor for potential chronic cardiovascular complications.

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
46
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
26
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
19
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
35